Dendritic cells (DCs) are APCs essential in regulating the immune response. PGE 2 , produced during inflammation, has a pivotal role in the maturation of DCs and, therefore, is vital for the immune response. The large variety of biologic functions governed by PGE 2 is mediated by its signaling through 4 distinct E-type prostanoid (EP) receptors. Immunogenic DCs express EP 2 and EP 4 , which mediate the PGE 2 signaling. However, the expression and function of EP receptors in human tolerogenic DCs (tol-DCs), which present an inhibitory phenotype, have not yet, to our knowledge, been assessed. To clarify the role of EP receptors in tolDCs, we examined the expression of different EP receptors and their effect using selective agonists in human cells. We find that EP 2 and EP 3 expression are up-regulated in in vitro-generated tol-DCs compared with mature DCs (mDCs). Activation of EP 2 -EP 4 has a direct effect on the surface expression of costimulatory molecules and maturation receptors, such as CD80, CD83, and CD86 or MHCII and CCR7 in tol-DCs, the latter being exclusively modulated by PGE 2 -EP 4 signaling. Importantly, we find that EP 2 and EP 3 receptors are involved in tolerance induction through IL-10 production by tol-DCs. These results are in sharp contrast with the inflammatory role of EP 4 . Moreover, we show that DCs generated in the presence of agonists for EP receptors, induce naive T cell differentiation toward polarized Th1/ Th17 cells. Given the differential effects of EP receptors, our results suggest that EP receptor agonist/ antagonists might become relevant novel drug templates to modulate immune response.
Introduction
DCs are a heterogeneous population of APCs that behave as a link between innate and adaptive immunity. They have a role in promoting both pro-and anti-inflammatory immune responses [1, 2] . iDCs mainly specialize in capturing Ags and presenting the processed epitopes to T cells via MHC I and II. Once iDCs are activated by specific receptors or proinflammatory cytokines, they mature to acquire the capacity to stimulate T cell responses. The maturation process includes the up-regulation of costimulatory proteins, such as CD80 and CD86, and maturation receptors, such as CD83 and MHC on the DC membrane, as well as the secretion of pro-or anti-inflammatory cytokines, such as IL-6, IL-12, IL-23, TNF-a, or IL-10. Moreover, to complete the maturation process, DCs acquire the ability to migrate from the peripheral tissues inside the lymph nodes by means of up-regulating CCR7 [3, 4] . The cytokine secretion pattern of activated DCs strongly defines the resulting polarization of Ag-specific, naive T cells, thereby determining the type of immune response toward Th1, Th2, or Th17 for immunity (IL-12, IL-23, and TNF-a) or tolerance through T regs [5] . These cytokines may influence directly on newly activated T cells, but more often, their production by DCs is amplified by positivefeedback signals that are provided by the differentiated T cells [6] .
To avoid undesired and exaggerated immune responses, the immune system is able to distinguish between innocuous and harmful Ags. For this, DCs have a crucial role, both in the generation of T cell immune responses against pathogens and, importantly, in maintaining immune tolerance to harmless Ags or their own body tissues [7, 8] . With the aim of achieving these opposite immunologic functions, different DC subsets participate either in immunity or tolerance, showing functional maturation and plasticity, depending on the environmental signals received [9, 10] .
Several protocols, including the generation of mo-DCs in the presence of corticosteroids, such as DEX and an MC or LPS activation to boost the tolerogenic properties, have been described to generate tol-DCs in vitro [11, 12] . These cells display a semimature phenotype of costimulatory molecules and maturation receptors, a pronounced shift toward antiinflammatory vs. proinflammatory cytokine production (greater amounts of IL-10 vs. lesser levels of IL-12) and a limited capacity to stimulate T cell response [13, 14] . The increased production of IL-10 upon bacterial stimuli by tol-DCs is considered critical to induce tolerance [13] . To achieve full mo-DCs maturation in vitro, PGE 2 is added in combination with a mixture of proinflammatory cytokines [15] [16] [17] , composed by IL-6, TNF-a, and IL-1b [18] . Of note, CCR7 expression in human DCs is directly dependent on PGE 2 stimulation [19, 20] .
PGs are secondary metabolites from arachidonic acid and are produced by COXs (constitutively active COX-1 and inducible COX-2) and PG synthases in response to an inflammation or stress stimuli [21] . PGE 2 exhibits pleiotropic biologic actions in a range of tissues among the immune system. PGE 2 is a key mediator of pyrexia, hyperalgesia, arterial dilation, or inflammation [22] [23] [24] . Furthermore, it is also involved in pathologies, such as cancer or autoimmune diseases. In the case of inflammation, it has been demonstrated that COX levels are augmented in inflamed tissues, such as patients with rheumatoid arthritis or arteriosclerosis, compared with healthy individuals, and are, therefore, correlated with high PGE 2 production [25, 26] .
The biologic activity of PGE 2 is mediated by 4 G proteincoupled receptor, known as receptors EP 1 -EP 4 . These receptors are associated to different G proteins, such as G i and G s , which induce different intracellular signaling cascades modulating the distinct functions of PGE 2 [27, 28] .
Several studies indicate that the presence of PGE 2 during DC maturation results in significant up-regulation of costimulatory molecules and maturation receptors CD80, CD83, MHC II, and the chemokine receptor CCR7 [29] . Furthermore, PGE 2 induces changes in cytokine production of DCs by inhibiting IL-12 or TNF-a [30] . Some studies have described an increase in IL-10 production in Mfs and mo-DCs when exposed to PGE 2 [31] . Moreover, PGE 2 is paramount during the priming of naive T cells, biasing T cell differentiation toward a Th2 response instead of Th1 [32] . Additionally, PGE 2 is involved in the enhancement of the local accumulation of T regs [33] . Recent studies showed that PGE 2 -EP 4 signaling in immunogenic DCs and T cells facilitates IL-23-dependent Th17 differentiation [29] . Indeed, EP 4 receptor appears to have a key role in the pathogenesis of some autoimmune diseases, such as rheumatoid arthritis [23, 34] .
Human mo-DCs express EP 2 and EP 4 , whereas EP 1 is undetectable at the mRNA level and EP 3 is almost negligible at the mRNA level but absent at the protein level [31] . Thus, PGE 2 exerts its biologic activity via EP 2 and EP 4 and differently regulates IL-12 or IL-23 cytokine production, depending on its concentration in the microenvironment. Additionally, it has been described that although EP 2 and EP 4 stimulate the second messenger cAMP, EP 2 mainly stimulates the protein kinase A pathway, which is directly dependent on cAMP, whereas EP 4 can both stimulate the protein kinase A or PI3K pathway, which could give different biologic actions [35] .
As part of the downstream machinery for PGE 2 signaling, CREB participates in a variety of cellular processes, including immune responses [36] . Thus, CREB has a key role in the production of IL-10, which, in turn, inhibits TLR-induced inflammation and prevents tissue damage [37] .
Concerning anti-inflammatory processes related to the immune system, PGE 2 also exerts a decisive role by releasing inhibitory cytokines and suppressing T cells. Although both EP 2 and EP 4 receptors were suggested to mediate all PGE 2 effects in mo-DCs, it has not yet been revealed whether the expression of EP receptors is similar in tol-DCs compared with immunogenic DCs. Moreover, the contribution of each individual receptor to the tolerogenic function, such as IL-10 production by tol-DCs or T cell polarization, has not yet, to our knowledge, been assessed. It is, therefore, important and relevant to gain insights on the effects of PGE 2 on tol-DCs and to unravel the role for each specific EP receptor signaling to mediate the tolerogenic effects.
In the present study, we investigated the regulatory role of PGE 2 in human tol-DCs. We have analyzed the expression of EP receptors in in vitro-generated tol-DCs using DEX as the tolerogenic factor and, in ex vivo, using purified conventional DCs (BDCA-1). In addition, we used specific agonists and antagonists of EP receptors to scrutinize the contribution of each EP receptor in the phenotype and cytokine production by tolDCs. Finally, we determined the effect of each single receptorsignaling pathway in naive T cell polarization. The biologic implications of different EP receptor signaling could be used in new therapeutic approaches to manipulate (modulate/ potentiate) the tolerogenic properties of DCs.
MATERIALS AND METHODS

Generation of tol-DCs
The present study was approved by the ethics committee at the Hospital Clinic of Barcelona, and the authors declare no violation of the Helsinki Doctrine on human experimentation. PBMCs were isolated from the buffy coats of healthy donors after Ficoll separation and were cultured for 2 h at 37°C to allow monocytes to adhere to the flask. Nonadherent cells, namely PBLs, were washed and cryopreserved. Monocytes adhering to the plate were cultured in X-VIVO 15 medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 2% AB human serum (Sigma-Aldrich, Madrid, Spain), IL-4 (300 U/ml), and GM-CSF (450 U/ml) (both from Miltenyi Biotec, Madrid, Spain) for 6 d to obtain iDCs. The MC, which is composed by IL-1b, IL-6 (both at 1000 U/ml), and TNF-a (500 U/ml) (CellGenix, Freiburg im Breisgau, Germany) plus PGE 2 (10 mg/ml) (Sigma-Aldrich) was added on d 6. To generate tolDCs, DEX (10 26 M) (Fortecortin; Merck, Madrid, Spain) was added on d 3.
For DC stimulation, 100 ng/ml of LPS (Sigma-Aldrich) were added on d 7 and incubated for 24 h. After stimulation, DC supernatant was collected for cytokine detection.
data, and empirical Bayes-moderated statistics were calculated using the limma package from Bioconductor (Seattle, WA, USA). P values were adjusted by determining false-discovery rates by the Benjamini-Hochberg procedure [39] . Microarray raw data (.cel files) and processed data have been uploaded in the Gene Expression Omnibus of the National Center for Biotechnology Information (Bethesda, MD, USA) and are accessible through GEO series accession number GSE56017.
RNA isolation
Total RNA was isolated with RNeasy Mini Kit columns (Qiagen, Hilden, Germany). RNA yield and purity were measured by means of the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). 
Real-time quantitative PCR
Flow cytometry analysis
To evaluate the DC phenotype, flow cytometry was performed. mAbs or their appropriate isotype controls were used: anti-CD80, CD83, and MHC II PElabeled (BD Pharmingen; BD Biosciences, San Diego, CA, USA). Anti-CCR7 (BD Biosciences Pharmingen) and a secondary anti-mouse PE-labeled (BD Biosciences). Flow cytometry was performed using FACSCanto II (BD Biosciences), and data were analyzed with BD FACSdiva 6.1TM software. Intracellular EP receptors staining were performed using anti-EP 2 , EP 3 . and EP 4 polyclonal Ab (Abcam, Cambridge, MA, USA) and a secondary anti-rabbit IgG PE-conjugated (Cell Signaling, Leiden, The Netherlands). Flow cytometry was performed using FACSCanto II, and data were analyzed with BD FACSdiva 6.1TM software.
EP agonists/antagonists experiments
Selective agonists and specific antagonists were used to study individual EP receptors function and signaling. Selective agonists (R)-butaprost (SigmaAldrich), sulprostone, L-902,688 (Cayman, Tallinn, Estonia) were used at a concentration of 100 nM in the engagement of EP 2 , EP 3 , and EP 4 receptors, respectively. EP receptor agonists were added on d 6 simultaneously with MC in substitution of PGE 2 .
Specific, competitive antagonists AH6809 (Cayman), L-798,106 (BioTechne, Minneapolis, MN, USA), GW627368X (Cayman), all at 1000 nM, were used to block EP 2 , EP 3 , and EP 4 receptors, respectively. Antagonists were added to tol-DCs culture on d 6 and were left for 2 h before the addition of MC plus PGE 2 .
Western blot analysis
Cell lysates and Western blot studies were performed with standard protocols. Polyvinylidene difluoride membranes were incubated with anti-EP 2 , EP 3 , and EP 4 polyclonal Ab (Abcam) and reproved with actin (Sigma-Aldrich). After washes, membranes were incubated for 2 h with HRP-conjugated, secondary Ab anti-rabbit (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Proteins were detected by ECL (ImageQuant LAS 4000; GE Healthcare Life Sciences, Barcelona, Spain) by means of ECL Western blotting detection reagent (GE Healthcare Life Sciences).
Sample preparation for confocal imaging
Chambered cover glasses (8 wells, Nunc Lab-Tek II; Thermo Fisher Scientific) were incubated with poly-L-lysine (10 mg/ml; Sigma-Aldrich) for 30 min at room temperature. Fresh cells were diluted up to a concentration of 5 3 10 6 /ml and were attached to the bottom of the cover glasses by incubation for 30 min. Cells were fixed using 4% paraformaldehyde and subsequently blocked with either 3% BSA for surface staining or 3% BSA and 0.2% Triton X-100 for intracellular staining. Staining with both primary (polyclonals from Abcam) and secondary anti-rabbit-AF488 (Thermo Fisher Scientific) Abs was performed for 45 min at room temperature in blocking buffer. Cells were then fixed again and stored upon imaging.
Confocal imaging
Imaging was performed using a confocal microscope (TCS SP5, Leica Microsystems, Buffalo Grove, IL, USA). Images were taken with a 1.4 numerical aperture, oil immersion objective (HCX PL APO CS 363.0; Leica Microsystems), a 512 3 512-pixel format, and a scanning speed of 400 Hz. EP receptors labeled with AF488 were excited with the 488 line of an argon laser at 25% of the power and detected between 495 and 560 nm. Images of several cells per field of view were taken, with a line accumulation of 3 times and a frame average of 6 times.
Cytokine production analysis IL-10, IL-12, and IL-23 production by DCs was analyzed by ELISA (eBioscience, San Diego, CA, USA), following the manufacturer's guidelines. Supernatant from T cell cultures was collected after 6 d of allogeneic response, and IFN-g (BD OptEIA; BD Biosciences) was analyzed by ELISA following the manufacturer's guidelines. 
Naive T cell polarization
BDCA-1 isolation
BDCA-1 cells were directly isolated from human PBLs with a BDCA-1 isolation kit (Miltenyi Biotec), following the manufacturer's instructions. For RNA extraction, pellets from 1 3 10 5 BDCA-1 cells were previously frozen. Then, RNA extraction was performed. For cytokine analysis, 2 3 10 4 BDCA-1 cells were cultured in X-VIVO 15 medium (Thermo Fisher Scientific) supplemented with 2% of AB human serum (Sigma-Aldrich). PGE 2 or EP receptor agonists were added. Cytokines were analyzed from the supernatant after 24 h of stimulation with heat-killed Escherichia coli at a 1:10 (DC:bacteria) ratio.
Statistical analysis
Results are shown as the means 6 SD. To determine statistical differences among the means, the paired-or independent-sample Mann-Whitney test was used for comparison of 2 conditions and ANOVA Kruskal-Wallis test for nonparametric data was performed when there were .2 conditions. Dunn post hoc test was applied to determine differences between 2 data sets. All conditions were compared with control tol-DCs generated with PGE 2 . Statistically significant differences were set at 0.05. Results are presented as *P , 0.05; **P , 0.01; or ***P , 0.001.
RESULTS
PGE 2 EP receptors are differentially expressed in tol-DCs
To unravel the expression of PGE 2 receptors and their regulation in previously characterized tol-DCs (generated from human monocytes using DEX and a maturation cocktail composed from IL-1b, IL-6, TNF-a, and PGE 2 ) [13, 40] , we examined the differential gene transcription of the 4 EP receptors between mDCs and tol-DCs by RT-PCR. Transcription levels for the EP 2 and EP 4 receptors revealed distinctive expression between tolDCs and mDCs. EP 2 was significantly up-regulated in tol-DCs compared with mDCs ( Fig. 1A) . In contrast, for the EP 4 receptors, no differences between mDCs and tol-DCs were found. Interestingly, RT-PCR revealed that EP 3 was also significantly upregulated in tol-DCs compared with mDCs. We also confirmed the absence of EP 1 in both DCs (data not shown). To confirm the mRNA data, the expression of the EP receptors was analyzed at the protein level by flow cytometry and Western blot. EP 2 and EP 3 were significantly up-regulated in tol-DCs compared with mDCs at the protein level, whereas, in agreement with mRNA, no differences for EP 4 were detected ( Fig. 1B and C ). In addition, fluorescent confocal microscopy images for EP 2 , EP 3 , and EP 4 were obtained for tol-DCs to evaluate their cellular location. Interestingly, Fig. 1D indicates that each EP receptor displays a unique subcellular localization. Although EP 2 is mainly distributed within the nucleus, EP 3 localizes on the cell membrane, and EP 4 is mostly found in intracellular vesicles surrounding the nucleus.
Phenotype of tol-DCs is modulated by EP 2 , EP 3 , and EP 4 -PGE 2 signaling
Several studies have confirmed that the presence of PGE 2 during maturation of immunogenic DCs translates into substantial up-regulation of costimulatory molecules and maturation receptors (CD80, CD83, or MHC II and CCR7) on DC surfaces [29] . It is, therefore, relevant to examine the effect of PGE 2 in tol-DCs, which exhibit a less-mature phenotype in response to the same maturation cocktail [13] . Hence, we evaluated the effect of PGE 2 on the tol-DC phenotype by measuring the expression of costimulatory molecules and maturation receptors using flow cytometry. As shown in Fig. 2A , the absence of PGE 2 from the maturation cocktail dramatically reduced the expression of CD80 (38.3% expression reduction; P = 0.026), CD83 (51.35% expression reduction; P = 0.0046), CD86 (62% expression reduction; P = 0.014), and MHC II (23.5% expression reduction; P = 0.045) on DCs. To decipher the individual contribution of each EP receptor to the tol-DC phenotype, PGE 2 was replaced in the maturation cocktail with a selective agonist for each receptor (A 2 , A 3 , and A 4 ), and the expression of costimulatory molecules was analyzed. As shown in Fig. 2B , all EP receptors have a redundant role in regulating the expression of CD80, CD83, CD86, and MHC II in tol-DCs because the presence of each agonist (A 2 , A 3 , and A 4 ) contributed to the up-regulation of these molecules to the same extent as PGE 2 . The addition of specific EP agonists did not cause any toxic effect in either DCs treated with the agonists (Supplemental Fig. 1A ).
In addition, we set up a complementary experiment using a specific antagonist to selectively block the signaling of each receptor (a2, a3, and a4). Consistently, the addition of a single specific antagonist to individually block the EP receptor did not interfere with the expression of costimulatory molecules (data not shown). In contrast, when all antagonists were added simultaneously, the expressions of the costimulatory molecules and MHC II were reduced, indicating that blocking of the EP receptors was complete (Supplemental Fig. 1D ). These results prove that signaling through only one of the EP receptors, regardless of which one, is sufficient to reach the maximum effect on the overall phenotype of tol-DCs. Of note, the viability of tol-DCs was not affected by EP receptor antagonist treatment (Supplemental Fig. 1B ). In addition, the specificity of the agonists was tests by the p-AKT pathway (Supplemental Fig. 1C) .
To sum up, we conclude that PGE 2 signaling regulates the expression of costimulatory and maturation molecules by all EP receptors expressed on tol-DCs.
CCR7 expression in tol-DCs is regulated by EP 4 signaling
It is well established that the expression of CCR7 in the cell surface of activated mDCs is directly dependent on PGE 2 . Although CCR7 expression in mo-DCs is very low or negligible upon tolerogenic treatment (around 20% of positive cells), it is still directly dependent on PGE 2 presence (results depicted in Supplemental Fig. 1D) . We examined the effect of a single EPreceptor activation using the selective agonists. CCR7 expression in tol-DCs was selectively induced by EP 4 agonist to a comparable extent as that induced by PGE 2 (Fig. 2C) but not by the agonists for EP 2 or EP 3 . Moreover, the generation of tol-DCs with all EP receptors agonists did not up-regulate CCR7 to an extent comparable to the effects observed with the EP 4 receptor agonist or PGE 2 (Fig. 2D ). In agreement with these findings, blocking signaling of PGE 2 through EP 4 inhibited the expression of CCR7 (Fig. 2E) . Remarkably, blocking EP 2 or EP 3 increased expression of CCR7 and caused a synergistic effect when both antagonists were added at the same time (Fig. 2F) . Thus, we can conclude that CCR7 expression is regulated by EP 4 receptor signaling.
IL-10 production by tol-DCs is partially induced by EP 2 and EP 3 receptors
To interrogate the relevance of PGE 2 in IL-10 production by tolDCs, we generated tol-DCs with or without PGE 2 in the MC. To raise IL-10 production, both tol-DCs were stimulated with LPS for 24 h, and the levels of IL-10 in the supernatant were quantified. As shown in Fig. 3A , IL-10 production by tol-DCs generated without PGE 2 was significantly reduced (by 50% 6 14.07) compared with tol-DCs generated with PGE 2 . The direct contribution of PGE 2 to the IL-10 production by tol-DCs was further demonstrated in a dose-response experiment showing that IL-10 production by activated tol-DCs was dependent on PGE 2 concentration (Fig. 3B) .
Given the significant reduction of IL-10 production by tol-DCs in the absence of PGE 2 and the fundamental implication of this cytokine in maintaining tolerance, we further tested the engagement of each EP receptor in IL-10 production. Thus, Figure 1 . Expression of EP receptors in tol-DCs. (A) Gene expression of EP receptors on tol-DCs. mRNA from mDCs and tol-DCs was extracted and converted into cDNA and then analyzed using RT-PCR. Graphs represent EP receptor gene expression relative to b-actin as arbitrary units (AU) means 6 SD of n = 7 independent donors. Mann-Whitney test for nonparametric data was used to compare differences between tol-DCs and mDCs. (B) Protein expression of EP receptors. Intracellular staining of EP 2 , EP 3 , and EP 4 receptors on DCs was performed and analyzed using flow cytometry. Results are displayed as means 6 SD of relative mean fluorescence intensity (MFI) of n = 5 independent donors. Mann-Whitney test for (continued on next page) PGE 2 in the maturation cocktail was replaced for selective agonists (A 2 , A 3 , and A 4 ), and IL-10 levels were analyzed. EP 2 or EP 3 signaling positively induced IL-10 release by tol-DCs, suggesting that both receptors are involved in IL-10 induction in tol-DCs. However, activation via EP 4 receptor drastically reduced IL-10 production by tol-DCs. Results were comparable to DCs generated without PGE 2 (Fig. 3C) . To further examine the interaction between the different receptors in IL-10 production, EP agonists were mixed and simultaneously added. As depicted in Fig. 3D , the combination of EP 2 and EP 3 receptor agonists had a synergic effect well beyond the general ligand PGE 2 , whereas combining either EP 2 or EP 3 agonists with the EP 4 agonist had an inhibitory effect on IL-10 production. As expected, the combined presence of the 3 agonists simultaneously had a comparable effect, albeit slightly lower than that of PGE 2 . With the goal of understanding the effect of signaling through different receptors, we selectively inhibited EP 2 , EP 3 , and EP 4 individually. Notably, impeding PGE 2 signaling through EP 2 or EP 3 reduced the release of IL-10 by tol-DCs to approximately 50% (Fig. 3E) . However, when EP 4 receptor was blocked, IL-10 production increased considerably (results displayed in Fig. 3C ). We obtained the same results by blocking 2 receptors at the same time with their corresponding antagonists, limiting signaling through only 1 receptor at a time, a similar scenario to when a specific agonist was used (Fig. 3F) . We next examined the downstream machinery of PGE 2 or the specific EP agonists signaling that, in the end, regulates the generation of IL-10. Thus, p-CREB was analyzed 10 min after adding PGE 2 or, alternatively, the specific EP agonists, to tol-DCs. High p-CREB levels were observed when tol-DCs were treated with PGE 2 , A 2 , or A 3 , whereas when the same cells were treated with the EP 4 agonist, the amount of p-CREB was comparable to tol-DCs generated without PGE 2 (Fig. 3G) . Overall, these results confirm the data shown in Fig. 3C and indicate that PGE 2 signaling, through both EP 2 and EP 3 , positively modulates IL-10 production in tol-DC, in contrast to signaling through EP 4 , which translates into an inhibitory effect.
PGE 2 -EP 4 receptor signaling inhibits IL-12 and promotes IL-23 production by tol-DCs
Although tol-DCs hardly generate proinflammatory cytokines, we focused on the production of inflammatory cytokines by tol-DCs and the effect of PGE 2 . We found that PGE 2 presence during tol-DC generation completely inhibited IL-12 release in response to LPS (Fig. 4A) . In contrast, in the absence of PGE 2 , tol-DCs produced significantly detectable amounts of IL-12 (Fig. 4A) , although the absolute concentration was relatively lower than in mDCs (data not shown). Moreover, IL-12 inhibition was dose dependent (Fig. 4B) . When tol-DCs were treated with EP agonists instead of PGE 2 , we found that the A 4 agonist mimicked the inhibition of IL-12 caused by PGE 2 , whereas A 2 and A 3 agonists did not influence IL-12 production (Fig. 4C) . Moreover, the combination of A 2 and A 3 agonists did not inhibit IL-12 generation by tol-DCs whereas the EP 4 signaling with a specific agonist abrogated IL-12 release, even in combination with A 2 or A 3 agonists (Fig. 4D) . To confirm these results, EP receptor antagonists were employed to block EP 2 , EP 3 , and EP 4 receptors. As shown in Fig. 4E , blocking EP 4 raised IL-12 production by tolDCs in response to LPS, whereas EP 2 or EP 3 blocking resulted in a marked decrease of IL-12 production, thereby suggesting a certain competition/balance among the 3 receptors. To further interrogate the effect of PGE 2 signaling through a single receptor, specific antagonists were mixed. A comparable effect to agonist treatment (Fig. 4C ) was detected when employing 2 antagonists. Hindering EP 2 and EP 3 receptors induced tol-DCs to release lower amounts of IL-12, whereas when EP 4 receptor was blocked, enhanced IL-12 production was observed (Fig. 4F) .
To shed some light on the mechanism by which PGE 2 influences other proinflammatory cytokines, we also assessed IL-23 levels. Similar to IL12p70 production, tol-DCs generated in the absence of PGE 2 produced more IL-23 than did tol-DCs generated with PGE 2 (Fig. 5A) , and IL-23 inhibition was PGE 2 -dose dependent (Fig. 5B) . Surprisingly, and in contrast to IL-12 release, A 4 agonist stimulation resulted in noticeably enhanced production of IL-23 by tol-DCs. On the other hand, activation of EP 2 or EP 3 receptors blocked generation of IL-23 to a similar extent to that of PGE 2 stimulation (Fig. 5C ). By using a combination of agonists, IL-23 levels increased in the presence of A 4 agonist, pointing to its direct stimulatory influence on IL-23 production (Fig. 5D ). As expected, blocking EP 2 or EP 3 receptors in tol-DCs resulted in enhanced generation of IL-23 (Fig. 5E) . However, EP 4 blocking did not have an effect on IL-23 release (Fig. 5E ). Blocking both EP 2 and EP 3 receptors produced comparable effects as that of A 4 stimulation. The similar trend could be observed when blocking EP 4 receptor in combination with either EP 2 or EP 3 receptors (Fig. 5F ). In conclusion, these results highlight the important role of EP 4 in positively modulating IL-23 production in human DCs that have previously received tolerogenic stimuli and underscore the tight balance of stimulation and inhibition among the 3 receptors.
Because IL-12 and IL-23 are composed of 2 heterogenic domains (more specifically, subunits p35 and p19, respectively) and share a p40 subunit, we hypothesized that the effects of inhibiting PGE 2 -EP 4 signaling on IL-12 production and stimulating IL-23 may rely on p35 and p19 subunit regulation. To assess the differences in regulation of the different subunits, we performed RT-PCR using specific primers for p35, p19, and p40. Results depicted in Supplemental Fig. 2A show that PGE 2 significantly inhibited p40 and p35 subunits, and consequently, IL-12 production by tol-DCs decreased. However, PGE 2 did not nonparametric data was used to compare differences between tol-DCs and mDCs. (C) Protein expression of EP receptors. Western blot analysis of the EP receptors was performed. Representative images of the bands for EP 2 , EP 3 , and EP 4 are shown (left panel). mDCs vs. tol-DCs percentage of relative expression of EP receptors with respect to b-actin is shown in the right graph. Results are presented as means 6 SD of n = 3 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions using tol-DCs PGE 2 -treated as a reference. (D) Confocal microscopy images of tol-DCs and EP 2 , EP 3 . and EP 4 receptors. Images correspond to a representative cAMP of 1 donor. ns, not significant. *P , 0.05; **P , 0.01. Figure 2 . PGE 2 modulates tol-DCs costimulatory molecules phenotype and CCR7 expression. Tol-DCs were generated using PGE 2 or its absence (unt). Selective EP receptors agonists (A 2 , A 3 , and A 4 ) were used to replace PGE 2 from MC, and selective antagonists (aEP 2 , aEP 3 , and aEP 4 ) were used to block single receptors in the presence of PGE 2 (DMSO was used as a vehicle). Costimulatory molecules (CD80 and CD86) and maturation markers (CD83, MHC II, and CCR7) were analyzed. (A) CD80, CD83, CD86, and MHC II expression on tol-DCs surface were analyzed by flow cytometry. Tol-DCs were treated with PGE 2 or its absence. Results are shown as relative mean fluorescence intensity (MFI; to isotype control) of n = 5 independent donors. Mann-Whitney test for nonparametric data was used to compare differences between the 2 conditions [PGE 2 and its absence (unt)]. (B) CD80, CD83, CD86, and MHC II expression on tol-DC surfaces were analyzed by flow cytometry. A 2 , A 3 , and A 4 EP receptors agonists (100 nM) were added to tol-DCs instead of PGE 2 . Results are presented as the percentage means 6 SD of costimulatory molecules and maturation receptors expression of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions, using tol-DCs with PGE 2 -treated as a reference. (C) CCR7 expression on tol-DCs surface was analyzed by flow cytometry. A 2 , A 3 , and A 4 EP receptors agonists (100 nM) were added to tol-DCs, instead of PGE 2 . Results are presented as percentage of CCR7 expression means 6 SD of n = 4 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions using tol-DCs PGE 2 -treated as a reference. (D) CCR7 expression on tol-DCs surface was analyzed by flow cytometry. Combination of A 2 , A 3 , and A 4 were added simultaneously. Results are presented as percentage of CCR7 expression means 6 SD of n = 3 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions using tol-DCs PGE 2 -treated as a reference. (E) CCR7 expression on tol-DC surfaces was analyzed by flow cytometry. aEP 2 -, aEP 3 -, aEP 4 -specific antagonists (1000 nM) were previously incubated for 2 h and then treated with PGE 2 . Results are presented as percentage of CCR7 expression means 6 SD of n = 3 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions, using tol-DCs PGE 2 -treated as a reference. (F) CCR7 expression on tol-DCs surface was analyzed by flow cytometry. The combination of aEP 2 and aEP 3 was added simultaneously. Results are expressed as the percentage of CCR7 expression means 6 SD of n = 4 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences between conditions using tol-DCs PGE 2 -treated as a reference. *P , 0.05; **P , 0.01; ***P , 0.001. Figure 3 . IL-10 production by tol-DCs partially induced by EP 2 and EP 3 receptors. Supernatants of tol-DCs were generated using PGE 2 or its absence (unt). Selective EP receptors agonists (A 2 , A 3 , and A 4 ) were used to replace PGE 2 from MC, and selective antagonists (aEP 2 , aEP 3 , and aEP 4 ) were used to block single receptors in the presence of PGE 2 (DMSO was used as a vehicle). Then, they were stimulated with LPS for 24 h and analyzed by ELISA for IL-10 production. (A) tol-DCs treated or unt with PGE 2 were analyzed. Results are plotted as relative IL-10 production (continued on next page) influence p19 in tol-DCs. Remarkably, the EP 4 receptor agonist distinctly induced p19 mRNA subunit expression, which could be responsible for the enhanced IL-23 levels shown in Fig. 5 [30, 41] . However, the effects of treating tol-DCs with PGE 2 on T cell differentiation remain unsolved.
To clarify how PGE 2 -treated tol-DCs drive T cell differentiation, tol-DCs generated with both PGE 2 and specific EP receptor agonists were cocultured with isolated naive T cells for 10 d. After in vitro expansion and differentiation, intracellular staining of cytokines was performed to characterize the T cell subset differentiation. A representative cytokine intracellular staining is showed in Fig. 6A . Naive T cells culture with tol-DCs generated in the presence of PGE 2 or its specific EP receptor agonist did not induce noticeable changes in Th1 differentiation, measured as the percentage of IFN-g-producing cells (Fig. 6B) . However, both tol-DCs in the absence of PGE 2 and in the presence of EP 4 agonist slightly increased Th17 differentiation (Fig. 6C) . Notably, a remarkable induction of double-positive (IFN-g/IL-17) Th1/ Th17 cells was detected when tol-DCs were treated with the EP 4 receptor agonist (Fig. 6D) . In contrast, tol-DCs produced in the presence of A 4 agonist resulted in a decrease (about 30% less) of IFN-g/IL-10-differentiated T cells (Fig. 6E) .
BDCA-1 circulating DCs express high levels of EP 2 receptor
Mo-DCs are widely used to generate human DCs. However, these cells illustrate an in vitro system to obtain DCs and could introduce some bias when compared with circulating DCs. To analyze the expression of the EP receptors and the role of PGE 2 in circulating DCs, we purified circulating BDCA-1 + DCs. The expression of EP receptors was analyzed together with cytokine production after being challenged with each specific agonist. RT-PCR results showed that BDCA-1-circulating DCs display greater expression of EP 2 receptor, in comparison to EP 4 receptor, at the mRNA level (Fig. 7A) . Moreover, the expression of EP 3 was less than that of EP 2 and EP 4 . These findings suggest a similar pattern of tol-DCs, which also up-regulate EP 2 . We confirmed these findings at the protein level by flow cytometry (Fig. 7B) .
BDCA-1 treated with PGE 2 or specific EP receptors agonists resulted in a clear enhancement of IL-10 production after 24 h stimulation with E. coli compared with nonstimulated BDCA-1. BDCA-1 purity is shown in Supplemental Fig. 2B . When BDCA-1 was treated with PGE 2 , EP 2 , or EP 3 agonists, IL-10 release by BDCA-1 was enhanced, in sharp contrast to the effect produced by the EP 4 receptor agonist, which inhibited IL-10 production (Fig. 7C) . These results suggest that, in circulating DCs, comparable to those in in vitro-generated tol-DCs, EP 2 and EP 3 are directly involved in IL-10 induction, whereas EP 4 is involved in its inhibition. Moreover, PGE 2 signaling in circulating DCs also inhibited IL-12 in response to E. coli, an effect that was similarly observed upon stimulation with specific EP agonists (Fig. 7D ).
DISCUSSION
Herein, we evaluated the expression and activity of EP receptors in human tol-DCs. Moreover, we shed light on the contribution of PGE 2 and its EP receptors to the tolerogenic profile of DCs. We report significant differential expression of EP between tolDCs and mDCs. Such differences included the up-regulation of EP 2 and EP 3 in tol-DCs at the mRNA and protein levels. We also studied the functional consequences of this particular EP upregulation and the effect of each individual receptor to the tolerogenic phenotype.
First, we analyzed the effect of PGE 2 on the tolerogenic phenotype of DCs. It is well established that PGE 2 is crucial for the optimal and final maturation of DCs [21, 31, 42] . Although tol-DCs display a semimature phenotype compared with mDCs [13] , costimulatory molecules and maturation receptors are also required for the initiation of a regulatory immune response with tolerogenic signals. It is important to highlight that, in the absence of PGE 2 , the expression of CD80, CD83, CD86, and MHC II was dramatically down-regulated in tol-DCs. Remarkably, when a single EP receptor was engaged with a specific agonist, (to PGE 2 -treated DCs) means 6 SD of n = 5 independent donors (absolute values ranged from 1000 to 5700 pg/ml for DCs treated with PGE 2 and 300 to 3000 pg/ml for unt tol-DCs). The Mann-Whitney test for nonparametric data was used to compare differences between the 2 conditions (PGE 2 and unt). (B) Different PGE 2 doses (0, 1, 100, and 1000 nM) were added to tol-DC cultures. Results are presented as picograms per milliliter means 6 SD of IL-10 production; in which, each line in the graph represents 1 of n = 3 independent donors analyzed. (C) A 2 , A 3 , and A 4 (100 nM) were used to stimulate DCs instead of PGE 2 . Results are presented as the relative IL-10 production (to PGE 2 -treated DCs) means 6 SD of n = 7 independent donors (absolute values ranged from 133 to 10,141 pg/ml). ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DC PGE 2 -treated as a reference. (D) Combination of A 2 , A 3 , and A 4 were used to check the synergies between EP receptors. Results are presented as picograms per milliliter means 6 SD of IL-10 production of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DC PGE 2 -treated as a reference. (E) aEP 2 , aEP 3 , and aEP 4 (1000 nM) were previously incubated for 2 h before adding PGE 2 . Results are presented as the percentage of relative IL-10 (to PGE 2 -treated DCs) secretions of n = 4 independent donors (absolute values ranged from 193 to 3241 pg/ml). ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions, using tol-DCs PGE 2 -treated as a reference. (F) aEP 2 , aEP 3 , and aEP 4 antagonist combination test was performed. Results are presented as relative IL-10 production (to PGE 2 -treated DCs) means 6 SD of n = 5 independent donors (absolute values ranged from 133 to 12,171 pg/ml). ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions, using tol-DCs PGE 2 -treated as a reference. (G) Western blot analysis was performed for p-CREB and CREB on tol-DCs. (Left) A representative picture of the bands for p-CREB, CREB, and b-actin is shown. (Right) The ratio of CREB phosphorylation means 6 SD of n = 5 donors is shown. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. *P , 0.05; **P , 0.01; ***P , 0.001. regardless of the receptor subtypes, we found a recovery of CD80, CD83, CD86, and MHC II expression. However, such differences were not observed when EP 2 , EP 3 , or EP 4 were challenged with a specific antagonist. These results indicate that PGE 2 signaling was comparable among all EP receptors expressed in tol-DCs, equally contributing to the phenotype. In contrast, although the EP 2 and EP 4 receptors have been described as sharing signaling pathways [29] , our results demonstrate that significant differences exist in CCR7 regulation and surface expression levels in tol-DCs, depending on which EP receptor is engaged with its specific agonist. CCR7 expression is associated with a complete maturation of DCs, which can then migrate to lymph nodes and initiate immune responses. Treating DCs with DEX have been described as translating into the tolerogenic phenotype and inhibiting CCR7 expression [19] . Our findings now show that CCR7 can be up-regulated by PGE 2 signaling through EP 4 . Because CCR7 is known to be involved in active inflammatory processes [3] , these results indicate that EP 4 signaling may have a more-inflammatory role than EP 2 or EP 3 signaling does in tol-DCs. Interestingly, blocking EP 2 and EP 3 simultaneously had a synergistic effect on increasing CCR7 expression. Combining the fact that tol-DCs express less CCR7 and more of both EP 2 and EP 3 than mDCs do, it is tempting to speculate that the inhibitory role of DEX in CCR7 expression is due to the up-regulation of EP 2 and EP 3 , counteracting the proinflammatory effect of PGE 2 signaling through EP 4 .
Tol-DCs are defined as producing considerable amounts of IL-10 in response to TLR ligands and gram-negative bacteria [13] . However, the role of PGE 2 in IL-10 production by tol-DCs remains unknown. In this study, we observed that PGE 2 is crucial in the regulation of this anti-inflammatory cytokine. In the absence of PGE 2 , IL-10 generation by tol-DCs was drastically reduced in response to LPS. Moreover, tol-DCs treated with increasing doses of PGE 2 also showed enhancement of IL-10 levels, confirming the direct pivotal role of PGE 2 in IL-10 production. To unfold which EP receptor influences the Figure 4 . PGE 2 -EP 4 receptor signaling inhibits IL-12 production by tol-DCs. Supernatants of tolDCs were generated using PGE 2 or its absence (unt). Selective EP receptors agonists (A 2 , A 3 , and A 4 ) were used to replace PGE 2 from MC and selective antagonists (aEP 2 , aEP 3 , and aEP 4 ) were used to block single receptors in the presence of PGE 2 (DMSO was used as a vehicle). Then, they were stimulated with LPS for 24 h and analyzed by ELISA for IL-12 production. (A) tol-DCs treated or unt with PGE 2 were analyzed. Results are presented as picograms per milliliter means 6 SD of IL-12 production of n = 5 independent donors. Mann-Whitney test for nonparametric data was used to compare differences between the 2 conditions (PGE2 and unt). (B) Different PGE 2 doses (0, 1, 100, and 1000 nM) were added to tol-DCs. Results are shown as picograms per milliliter of IL-12 production; in which, each line in the graph represents 1 of n = 3 independent donors analyzed. (C) A 2 , A 3 , and A 4 (100 nM) were used to stimulate DCs instead of PGE 2 . Results are presented as the relative IL-12 production (to PGE 2 -treated DCs) means 6 SD (absolute values ranged from 0 to 287 pg/ml) of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions, using tol-DCs PGE 2 -treated as a reference. (D) Combination of A 2 , A 3 , and A 4 agonists were used to check the synergies between EP receptors. Results are presented as picograms per milliliter means 6 SD of IL-12 production of n = 5 independent donors. (E) aEP 2 , aEP 3 , and aEP 4 (1000 nM) were previously incubated for 2 h before adding PGE 2 . Results are presented as picograms per milliliter means 6 SD of IL-12 secretion of n = 4 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions, using tol-DCs PGE 2 -treated as a reference. (F) An aEP 2 , aEP 3 , and aEP 4 antagonist combination was performed. Results are displayed as relative IL-12 production means 6 SD of n = 5 independent donors (absolute values ranged from 3 to 378 pg/ml). ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. *P , 0.05; ***P , 0.001. production of IL-10 by tol-DCs, we employed receptor-specific agonists. When EP 2 and EP 3 were engaged with the specific agonists, IL-10 was substantially increased. In contrast, EP 4 -receptor signaling inhibited IL-10 production. To further scrutinize the effect of PGE 2 signaling through a combination of different receptors, we added EP receptor antagonists to block specific receptors. We confirmed that PGE 2 signaling through EP 2 and EP 3 has an effect on the generation of IL-10 by tol-DCs, whereas EP 4 receptor signaling impedes IL-10 release. These results were further confirmed by measuring the degree of CREB phosphorylation, a transcription factor that is crucial for IL-10 production [36] . Indeed, we showed that CREB was phosphorylated upon EP 2 and EP 3 activation with specific agonists and not by EP 4 activation.
In the present study, we established that PGE 2 modulates the production of inflammatory cytokines IL-12 and IL-23 in tol-DCs via EP 4 . In the case of IL-12, EP 4 is directly involved in its inhibition, mediated by PGE 2 , because only the EP 4 agonist was able to alter IL-12 production in tol-DCs. To our surprise, we discovered that the EP 4 agonist considerably enhanced the release of IL-23. Based on these results, we conclude that, although EP 4 activation negatively regulates IL-12, it positively induces IL-23. Although it may seem contradictory that EP 4 differentially regulates IL-23 and IL-12, RT-PCR of p19, p40, and p35 subunits confirmed that EP 4 activation up-regulated p19, whereas overall p40 and p35 were inhibited by both PGE 2 and EP 4 receptor activation. Altogether, our data suggest that EP 4 behaves as a proinflammatory receptor in tol-DCs because its signaling inhibits IL-10 production and simultaneously enhances IL-23. In line with our results, recent findings were published showing that activation of EP 4 induced p19 up-regulation in mo-DCs maturated with TNF-a [31] .
Furthermore, we also identified EP 3 as an inducer of IL-10 production in tol-DCs. Nevertheless, this receptor has been classically described as being coupled to G i proteins and, therefore, inhibiting cAMP mobilization. In contrast, recent Figure 5 . PGE 2 -EP 4 signaling promotes IL-23 production by tol-DCs. Supernatants of tol-DCs were generated using PGE 2 or its absence (unt). Selective EP receptors agonists (A 2 , A 3 , and A 4 ) were used to replace PGE 2 from MC, and selective antagonists (aEP 2 , aEP 3 , aEP 4 ) were used to block single receptors in the presence of PGE 2 (DMSO was used as a vehicle). Then, they were stimulated with LPS for 24 h were analyzed by ELISA for IL-23 production. (A) tol-DCs treated or unt with PGE 2 were analyzed. Results are presented as picograms per milliliter means 6 SD of IL-23 production of n = 5 independent donors. Mann-Whitney test for nonparametric data was used to compare differences between the 2 conditions (PGE2 and unt). (B) Different doses of PGE 2 (0, 1, 100, and 1000 nM) were added to tol-DCs. Results are shown as picograms per milliliter of IL-23 production; in which, each line in the graph represents 1 of n = 3 independent donors analyzed. (C) A 2 , A 3 , and A 4 (100 nM) were used to stimulate DCs instead of PGE 2 .
Results are presented as means 6 SD of IL-23 production of n = 5 independent experiments. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. (D) Combination of A 2 , A 3 , and A 4 was used to check the synergies between EP receptors. Results are presented as picograms per milliliter means 6 SD of IL-23 production of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. (E) aEP 2 , aEP 3 , and aEP 4 (1000 nM) were previously incubated for 2 h before adding PGE 2 . Results are presented as picograms per milliliter means 6 SD of IL-23 secretion by tol-DC of n = 4 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. (F) An aEP 2 , aEP 3 , and aEP 4 antagonist combination was performed. Results are presented as picograms per milliliter means 6 SD of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. ns, not significant. *P , 0.05; **P , 0.01. studies have shown that there are some splicing variants of EP 3 that can couple with G s proteins and, therefore, act through cAMP as well. We propose that EP 3 in tol-DCs behaves similarly to EP 2 , by mobilizing cAMP, thereby contributing to the tolerogenic profile, which represents a new role for PGE 2 EP 3 signaling [43, 44] .
The particular expression pattern and subcellular localizations of EP receptors in tol-DCs suggest a different role for each EP receptor in its tolerance function. We propose that different location is due to the different behavior of the EP receptors once they have been in contact with PGE 2 . In addition, our results are in concordance with a study that found the EP 4 receptor location in the nucleus [45] . Revisiting the roles of different EP receptors in cancer development, a large body of evidence supports the notion that EP receptors are of utmost importance in mediating the overall protumorigenic action of PGE 2 [46] . There are different roles for each EP receptor in cancer development. In this sense, EP 2 is relevant in a variety of cancers because it has been described as being involved in COX-2 regulation and, therefore, PGE 2 production. Moreover, EP 2 has a key role in the generation of myeloid-derived suppressor cells. Recent studies pointed to EP 4 as a candidate tumor-suppressor gene, in contrast to other studies that have found a role for it in promoting growth and progression of cancer [42, 47, 48] . Furthermore, the effect of EP 3 in cancer has not yet been disclosed. However, there have been some indirect implications, such as in angiogenesis [43] . These clear differential roles of EP 2 , EP 3 , and EP 4 observed in cancer could be connected with the tolerogenic profile observed in our results. Thus, it is conceivable that EP 2 and EP 3 are involved in creating the tolerogenic environment around the tumor, favoring escape from the immune system and its subsequent survival and progression.
Some studies have recently reported that mo-DCs treated with PGE 2 facilitate Th1 differentiation in addition to its main characteristic of biasing T cells to the Th2/Th17 phenotype [30] . However, the effects of PGE 2 -treated tolerogenic DCs on T cell have not, to our knowledge, been reported. In the present study, we have found that tol-DCs treated with an EP 4 agonist considerably biased naive T cells toward a double-positive IFN-g + /IL-17 + profile (Th1/Th17). Moreover, PGE 2 -EP 4 signaling also has a tendency to inhibit IL-10 + /IFN-g + cell bias. In addition, our data on T cell polarization did not show any differences regarding Th1 (IFN-g + ) differentiation. We hypothesized that the significant increase in Th1/Th17 population could be related to the fact that EP 4 signaling increases IL-23 production [49] [50] [51] .
To investigate whether the tolerogenic role of EP 2 and EP 4 was also relevant in circulating DCs, we purified, from the peripheral blood of healthy donors, BDCA-1 + cells, which IL-10 releases upon bacteria stimulation [52] . We found that EP 2 was highly expressed in BDCA-1 + DCs. In agreement with our in vitro results, BDCA-1 treated with PGE 2 generated high amounts of IL-10. Moreover, specific challenges of EP 2 or EP 3 receptor were responsible for that IL-10 production. In contrast, EP 4 signaling did not result in IL-10 production. The increased expression of EP 2 could balance PGE 2 to signal via this receptor, although it has lower affinity for PGE 2 than EP 4 receptor does in human cells. However, further studies are needed to investigate Figure 7 . Circulating DC BDCA-1 cells up-regulated EP 2 receptor, which is involved IL-10 production. (A) EP receptor gene expression on BDCA-1 DCs. mRNA from BDCA-1 was extracted and then analyzed using RT-PCR. Graphs represent EP receptor gene expression relative to b-actin as arbitrary unit (AU) means 6 SD of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. (B) EP receptor protein expression on BDCA-1 DCs. Extracellular staining of EP 2 , EP 3 , and EP 4 receptors on DCs was performed and analyzed using flow cytometry. Results are displayed as means 6 SD of relative mean fluorescence intensity (MFI) of n = 3 independent donors. (C) BDCA-1 cells were challenged with PGE 2 or EP receptor agonists A 2 , A 3 , and A 4 (100 nM) and E. coli for 24 h. IL-10 production was measured by ELISA. Results are presented as picograms per milliliter of IL-10 of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference.
(D) BDCA-1 cells were challenged with PGE 2 or EP receptor agonists A 2 , A 3 , and A 4 (100 nM) and E. coli for 24 h. IL-12 production was measured by ELISA. Results are presented as picograms per milliliter of IL-10 of n = 5 independent donors. ANOVA Kruskal-Wallis test for nonparametric data was used to compare differences among conditions using tol-DCs PGE 2 -treated as a reference. *P , 0.05; **P , 0.01; ***P , 0.001.
individual EP receptor expression and signaling in various human in vivo-occurring DCs subsets. In summary, our results show a different role for each EP receptor's signaling, regulating important receptors and cytokine production in in vitro-derived tol-DCs and circulating BDCA-1 cells. Therefore, manipulation of these EP receptors could result in therapeutic targets to accentuate the tolerogenic or inflammatory properties. Along these lines, there are several studies to take advantage of EP 4 receptor agonists and antagonists as potential novel drugs for manipulating the immune response. Accordingly, the pharmaceutical industry has launched EP 4 drug development programs, and a variety of EP 4 receptor agonists and antagonists are available for experimental studies and further clinical development. Although systemic administration of EP 4 receptor antagonists might be well tolerated, agonists are better administered locally in the tissue in which they are needed, thereby avoiding systemic side effects [53] .
CONCLUSIONS
To sum up, in the present study, we report the differential expression of EP receptors in tol-DCs treated with DEX. We report the up-regulation of EP 2 and EP 3 at both the mRNA and protein levels. Moreover, both receptors have been associated with a tolerogenic profile because of the induction of high IL-10 levels. In addition, none of these receptors regulate the production of proinflammatory cytokines, such as IL-12 or IL-23, in tol-DCs. In contrast, EP 4 signaling has a proinflammatory effect by inhibiting IL-10 and increasing IL-23 production. Furthermore, we have found that EP 4 signaling has a functional effect on tol-DCs that biases naive T cell polarization toward a double Th1/Th17 (IFN-g + /IL-17 + ) profile. Notably, we observed that EP 2 and EP 3 receptors are both highly expressed in circulating BDCA-1 cells, and their activation contributed to the generation of IL-10 in response to gram-negative bacteria. Overall, our work suggests that PGE 2 exerts both pro-and antiinflammatory roles by engaging different EP receptors in tol-DCs. Insight into the delicate balance between opposite signals and how to manipulate them is of utmost relevance in the treatment of both cancer and autoimmune diseases. AUTHORSHIP G.F.-G. designed and performed research, analyzed and interpreted data, and wrote the manuscript. R.C. performed research and analyzed and interpreted data. K.J.E.B. and C.E. performed research. J.J.L. contributed vital analytic tools. M.F.G.-P. designed research and interpreted data. D.B.-R. designed research, analyzed and interpreted data, and wrote the manuscript.
